Second Sight’s legacy product, Argus® II, approved by the FDA for the treatment of retinitis pigmentosa, has been implanted in 350+ individuals worldwide, restoring functional, artificial vision by renewing light perception and transforming the daily experience in the majority of individuals.

Authorized by Federal (U.S.) law to provide electrical stimulation of the retina to induce visual perception in blind patients with severe to profound retinitis pigmentosa and bare light or no light perception in both eyes. The effectiveness of this device for this use has not been demonstrated.